Information about the case is still scarce.

Aegirbio writes in a press release that it has until January 2 to announce how it wants to express itself in the case.

"Before then, the company has no opportunity to comment on the matter further," it says.

Aegirbios was last year's big hit company with a share price that surged during the summer after a series of press releases about the multi-million dollar sale of the company's covid test to Asia.

But last autumn the curve turned – and several news changed the image of the businesses:

• SVT showed that Aegirbio's partner companies could be linked to the so-called mobile network, with suspected VAT frauds in the billions range.

• Aegirbio had neglected to say that it had received a rejection of an application from the Medical Products Agency to obtain a dispensation for home tests in Sweden.

• In its own interim reports, Aegirbio was repeatedly forced to backtrack on its previous success messages.

• Experts said Aegirbio's message may have broken the law.

While thousands of small savers saw their values ​​go up in smoke, it turned out that an ownership company managed to make a huge profit - in a chain of companies with several connections to Aegirbio's current CEO.

Stopped answering questions

Aegirbio's management has repeatedly denied all allegations of impropriety, and referred all inaccuracies to the former partner company - which in turn claimed that it was Aegirbio that exaggerated the happy messages.

Aegirbio's board chairman announced last autumn that it did not intend to answer any more questions from SVT Nyheter, citing "strongly biased negative publications with dubious advertisements and headlines".

However, both current and former shareholders have continued to demand answers from the company, and have also made notifications to both the authorities and Nasdaq, where Aegirbio is traded on the First North marketplace.

And so it is Nasdaq that has now started an investigation which, according to Aegirbio's own press release, has been handed over to the Stock Exchange's disciplinary committee - with a request for delisting.

Javascript is disabled

Javascript must be enabled to play video

Read more about browser support

Ronny Jansson is one of many who lost hundreds of thousands of kroner when the medtech company Aegirbio crashed on the stock exchange.

- All of a sudden my savings were up to 1.6 million.

It was fucking fun.

Then when you realize that it is based on bluff claims, it feels less good.

Photo: Tomas Hallstan/SVT